ArticleBMC microbiology2022
Effects of lactoferrin on intestinal flora of metabolic disorder mice.
Article in BMC microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Lactoferrin as a Non-Hormonal Therapeutic Candidate for Endometriosis: Mechanisms and Future Directions.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Whey Proteins and Bioactive Peptides: Advances in Production, Selection and Bioactivity Profiling.Biomedicines · 2025Review
- Effects of a Novel Bovine Lactoferrin-Derived Peptide on the Intestinal Morphology and Intestinal Flora in Rats.Microorganisms · 2025Article
- Comparative in silico and in vivo study of the antioxidant activity of lactoferrin, Geobacillus stearothermophilus, and Lactobacillus delbrueckii subsp. lactis against Rotavirus infection in male mice.BMC microbiology · 2025Article
- Role of lactoferrin and its derived peptides in metabolic syndrome treatment.Frontiers in endocrinology · 2025Review
- Association analysis of gut microbiota with LDL-C metabolism and microbial pathogenicity in colorectal cancer patients.Lipids in health and disease · 2024Article
- Impact of High-Temperature Feeds on Gut Microbiota and MAFLD.Journal of microbiology and biotechnology · 2024Article
- Investigating the modulatory effects of lactoferrin on depressed rats through 16S rDNA gene sequencing and LC-MS metabolomics analysis.Scientific reports · 2024Article
- Lactoferrin alleviates chronic low‑grade inflammation response in obese mice by regulating intestinal flora.Molecular medicine reports · 2024Article
- Research Progress on New Functions of Animal and Plant Proteins.Foods (Basel, Switzerland) · 2024Review
- Milk Bioactive Compounds and Gut Microbiota Modulation: The Role of Whey Proteins and Milk Oligosaccharides.Foods (Basel, Switzerland) · 2024Review
- Exploring the modulatory role of bovine lactoferrin on the microbiome and the immune response in healthy and Shiga toxin-producing E. coli challenged weaned piglets.Journal of animal science and biotechnology · 2024Article
- Gut microbiota and metabolomics unveil the mechanisms ofFrontiers in pharmacology · 2024Article
- To Boost or to Reset: The Role of Lactoferrin in Energy Metabolism.International journal of molecular sciences · 2023Review
- Gene-Diet Interactions: Viability of Lactoferrin-Fortified Yoghurt as an Element of Diet Therapy in Patients Predisposed to Overweight and Obesity.Foods (Basel, Switzerland) · 2023Article
- The Role of Lactoferrin in Intestinal Health.Pharmaceutics · 2023Review
- Liuwei Dihuang formula ameliorates chronic stress-induced emotional and cognitive impairments in mice by elevating hippocampal O-GlcNAc modification.Frontiers in neuroscience · 2023Article
- Lactoferrin alleviates Western diet-induced cognitive impairment through the microbiome-gut-brain axis.Current research in food science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To study the mechanism of lactoferrin (LF) regulating metabolic disorders in nutritionally obese mice through intestinal microflora. Twenty-one male C57BL/6 mice were randomly divided into 3 groups: control group, model group and LF treatment group. The mice in control group were fed with maintenance diet and drank freely. The mice in model group were fed with high fat diet and drank freely. The mice in LF treatment group were fed with high fat diet and drinking water containing 2% LF freely. Body weight was recorded every week. Visceral fat ratio was measured at week 12. Blood glucose and serum lipid level were detected by automatic biochemical analyzer. The gut microbiota of mice was examined using 16 s rRNA sequencing method. LF treatment significantly reduced the levels of visceral adipose ratio, blood glucose, triglyceride, total cholesterol and low-density lipoprotein cholesterol (LDL-C) in high-fat diet mice (p < 0.05). It can be seen that drinking water with 2% LF had a significant impact on metabolic disorders. At the same time, the Firmicutes/Bacteroidetes ratio(F/B) of LF treated mice was decreased. The abundance of Deferribacteres, Oscillibacter, Butyricicoccus, Acinetobacter and Mucispirillum in LF treatment group were significantly decreased, and the abundance of Dubosiella was significantly increased (p < 0.05). In the LF-treated group, the expression levels of glucose metabolism genes in gut microbiota were increased, and the expression levels of pyruvate metabolism genes were decreased. It can be seen that metabolic disorders were related to intestinal flora. In conclusion, LF regulates metabolic disorders by regulating intestinal flora.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.